- Home
- AVTX vs QNCX Comparison
AVTX vs QNCX Comparison
Compare AVTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | QNCX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 17.5M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AVTX | QNCX |
|---|---|---|
| Price | $15.48 | $31.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 908.0K | 15.4K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $12.41 | $0.08 |
| 52 Week High | $24.27 | $35.41 |
Technical Indicators
Market Signals| Indicator | AVTX | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 53.67 |
| Support Level | $15.29 | $29.95 |
| Resistance Level | $20.54 | $35.38 |
| Average True Range (ATR) | 1.08 | 2.10 |
| MACD | -0.18 | -0.16 |
| Stochastic Oscillator | 16.07 | 65.49 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.